HUP0004396A2 - A lipoprotein-oxidáció gátlására szolgáló, hatóanyagként hidroxilezett koleszterincsökkentő szert tartalmazó gyógyszerkészítmények - Google Patents

A lipoprotein-oxidáció gátlására szolgáló, hatóanyagként hidroxilezett koleszterincsökkentő szert tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0004396A2
HUP0004396A2 HU0004396A HUP0004396A HUP0004396A2 HU P0004396 A2 HUP0004396 A2 HU P0004396A2 HU 0004396 A HU0004396 A HU 0004396A HU P0004396 A HUP0004396 A HU P0004396A HU P0004396 A2 HUP0004396 A2 HU P0004396A2
Authority
HU
Hungary
Prior art keywords
inhibitor
pharmaceutical compositions
compositions containing
lowering agent
cholesterol lowering
Prior art date
Application number
HU0004396A
Other languages
English (en)
Inventor
Michael Aviram
Charles Larry Bisgaier
Roger Schofield Newton
Mira Rosenblat
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HUP0004396A2 publication Critical patent/HUP0004396A2/hu
Publication of HUP0004396A3 publication Critical patent/HUP0004396A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A lipoproteinek oxidációjának gátlására szolgáló találmány szerintigyógyszerkészítményekben hatóanyagként ismert koleszterincsökkentőszerek hidroxilezett származékait alkalmazzák, pl. hidroxilezett gemfibrozilt, atorvastatint vagy fluvastatint. A koleszterincsökkentőszerek hidroxilezett származékai felhasználhatók az atherogenesiskifejlődésének, valamint az ennek következményeként kialakulóvascularis betegségek, köztük a szívrohamok megelőzésére. Ó
HU0004396A 1997-11-25 1998-11-04 Pharmaceutical compositions containing hydroxylated cholesterol lowering agent as inhibitor of lipoprotein oxidation HUP0004396A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6688897P 1997-11-25 1997-11-25
PCT/US1998/023483 WO1999026583A2 (en) 1997-11-25 1998-11-04 Inhibtion of lipoprotein oxidation

Publications (2)

Publication Number Publication Date
HUP0004396A2 true HUP0004396A2 (hu) 2001-06-28
HUP0004396A3 HUP0004396A3 (en) 2003-04-28

Family

ID=22072341

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004396A HUP0004396A3 (en) 1997-11-25 1998-11-04 Pharmaceutical compositions containing hydroxylated cholesterol lowering agent as inhibitor of lipoprotein oxidation

Country Status (23)

Country Link
US (1) US6362236B1 (hu)
EP (1) EP1047421A2 (hu)
JP (1) JP2001523694A (hu)
KR (3) KR100539644B1 (hu)
CN (1) CN1160068C (hu)
AR (1) AR015487A1 (hu)
AU (1) AU759376B2 (hu)
BR (1) BR9815039A (hu)
CA (1) CA2303864A1 (hu)
CO (1) CO4970835A1 (hu)
HK (1) HK1033095A1 (hu)
HU (1) HUP0004396A3 (hu)
IL (1) IL135154A (hu)
IS (1) IS5413A (hu)
NO (1) NO20002639L (hu)
NZ (1) NZ503598A (hu)
PE (1) PE134199A1 (hu)
PL (1) PL341397A1 (hu)
TR (1) TR200001522T2 (hu)
TW (1) TW552137B (hu)
UY (1) UY25268A1 (hu)
WO (1) WO1999026583A2 (hu)
ZA (1) ZA9810743B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
US7250304B2 (en) * 2000-03-31 2007-07-31 The Regents Of The University Of California Functional assay of high-density lipoprotein
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
PT2404890T (pt) 2003-01-23 2017-10-23 Esperion Therapeutics Inc Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
US20060194981A1 (en) * 2005-02-26 2006-08-31 Jass Paul A Process for preparation of probucol derivatives
WO2006104399A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
CN104042617A (zh) 2009-04-29 2014-09-17 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
US8298554B2 (en) 2009-04-29 2012-10-30 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
PT2443246T (pt) 2009-06-15 2018-03-14 Amarin Pharmaceuticals Ie Ltd Composições e métodos para reduzir os triglicéridos sem aumentar os níveis de ldl-c num indivíduo em terapia de estatinas concomitante
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
NZ743706A (en) 2012-06-29 2019-08-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
KR101665180B1 (ko) 2014-07-01 2016-10-14 순천향대학교 산학협력단 아포지단백질 a-i 돌연변이체 g59v를 포함하는 항산화성 펩타이드 및 이를 포함하는 항산화 조성물
CN114099496A (zh) 2015-03-13 2022-03-01 艾斯柏伦治疗公司 含etc1002和依泽替米贝的组合及治疗方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MX2021002553A (es) 2018-09-24 2021-04-29 Amarin Pharmaceuticals Ie Ltd Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
WO2020257571A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Methods of making bempedoic acid and compositions of the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles

Also Published As

Publication number Publication date
CN1279605A (zh) 2001-01-10
CA2303864A1 (en) 1999-06-03
TW552137B (en) 2003-09-11
UY25268A1 (es) 1999-07-19
PL341397A1 (en) 2001-04-09
HUP0004396A3 (en) 2003-04-28
US6362236B1 (en) 2002-03-26
IL135154A0 (en) 2001-05-20
CN1160068C (zh) 2004-08-04
HK1033095A1 (en) 2001-08-17
KR20050113288A (ko) 2005-12-01
AU1518899A (en) 1999-06-15
WO1999026583A3 (en) 1999-12-09
CO4970835A1 (es) 2000-11-07
EP1047421A2 (en) 2000-11-02
KR20010032401A (ko) 2001-04-16
ZA9810743B (en) 1999-05-31
NZ503598A (en) 2002-06-28
BR9815039A (pt) 2001-03-20
TR200001522T2 (tr) 2000-12-21
PE134199A1 (es) 2000-01-20
IL135154A (en) 2005-05-17
AU759376B2 (en) 2003-04-10
NO20002639D0 (no) 2000-05-23
IS5413A (is) 2000-03-24
AR015487A1 (es) 2001-05-02
WO1999026583A2 (en) 1999-06-03
KR100539644B1 (ko) 2005-12-29
KR20050086975A (ko) 2005-08-30
JP2001523694A (ja) 2001-11-27
KR100586754B1 (ko) 2006-06-08
NO20002639L (no) 2000-05-23

Similar Documents

Publication Publication Date Title
HUP0004396A2 (hu) A lipoprotein-oxidáció gátlására szolgáló, hatóanyagként hidroxilezett koleszterincsökkentő szert tartalmazó gyógyszerkészítmények
MA28102A1 (fr) Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
DE69534564D1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure-derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
ATE212351T1 (de) Androsten-derivate
TNSN97015A1 (fr) Nouveaux derives de 19-nor-pregnene.
BR9908280A (pt) Inibidores de enzimas de fosfolipase
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
DE69833010D1 (de) Cannabinol-11-säurederivate als entzündungshemmer und analgetika
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
BR9811099A (pt) Inibidores de urocinase
DE69838099D1 (de) Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
DE69819539D1 (de) Antithrombotische mittel
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung
HUP0101354A2 (hu) E-2-[4-(4-klór-1,2-difenil-1-butenil)-fenoxi]-etanol észterei, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees